Vai alla homepage
Saban Sec
14
anni di esperienza

Saban Sec

  • Specializzazione: Clinical oncologist
  • 14 anni di esperienza
  • Lingue parlate:
    Turkish
  • Studio medico: Turkey, Istanbul, Valued Med Hub Hospitals
  • Turkish Medical Oncology Association Specialist Physicians Representative since 2022. Member of Istanbul Medical Chamber and Turkish Medical Oncology Association.

    Dr. Saban Sec is a medical oncologist with experience at leading hospitals, including Haseki Training and Research Hospital, Prof. Dr. Cemil Taşcıoğlu City Hospital, and Bahçelievler Medikalpark Hospital. He currently represents specialist physicians in the Turkish Medical Oncology Association. He is also a member of the Istanbul Medical Chamber and the Turkish Medical Oncology Association.

    Dr. Sec treats breast, lung, gastrointestinal, prostate, urogenital, head and neck cancers, as well as sarcomas and rare tumors. He has published many peer-reviewed articles on cancer prognosis, treatment outcomes, and survival rates. His research includes studies with large patient groups, such as 138 patients with HER2-positive metastatic gastric cancer. Dr. Sec focuses on prognostic factors and treatment responses in different cancers. He is dedicated to improving cancer care.

4.9
Punteggio eccellente
20 recensioni verificate dei pazienti
1 stelle
0%
2 stelle
0%
3 stelle
0%
4 stelle
0%
5 stelle
100%

Recensioni dei pazienti

Informazioni sulla clinica Valued Med Hub Hospitals
Questo medico non ha recensioni, ma puoi consultare quelle della clinica dove lavora.
La tua fiducia è la nostra priorità principale
Valutiamo la tua fiducia sopra ogni cosa, quindi le cliniche non possono pagare per modificare o rimuovere le recensioni.
Scopri di più sulle recensioni.
1-5 di 20 recensioni
Peter Tin Shouk Fong
10 lug 2025
Recensione verificata.
I am very impressed with the quality and standard of the whole process
Abdoul wahab Ka
21 mag 2025
Recensione verificata.
the coach's availability, his empathy and his humanism
Vikki Kingsley Jones
9 ago 2024
Recensione verificata.
I recommend bookimed
Recensione anonima
7 mar 2025
Recensione verificata.
It’s so world changing to be able to see clearly again!
Valerii Stasenko
11 feb 2025
Recensione verificata.
Thank you very much and I will recommend this clinic to everyone I know
Vedi altro

Servizi medici

Vedi altro

Com'è andata la tua esperienza?

1 di 3
Le informazioni su questo medico sono complete e chiare
1
2
3
4
5
Totalmente in disaccordo
Totalmente d'accordo

Formazione accademica

Experience

2012-2017 Haseki Training and Research Hospital Internal Medicine

2017 Kanuni Sultan Süleyman Training and Research Hospital Internal Medicine Specialist Dr.

2017-2021 Prof. Dr. Cemil Taşcıoğlu City Hospital Medical Oncology

2021-2022 Şanlıurfa Mehmet Akif İnan EAH Medical Oncology Specialist Dr.

2022 Bahçelievler Medikalpark Hospital

2022- Turkish Medical Oncology Association Specialist Physicians Representative

 

Professional Memberships

1) Istanbul Medical Chamber Member

2) Turkish Medical Oncology Association Member

 

Areas of Interest

1) Breast cancer,

2) Lung cancer

3) Gastrointestinal (colon, rectum, stomach, liver) cancers

4) Prostate cancer

5) Urogenital cancers

6) Head, neck cancers

7) Sarcoma treatments

8) Rare tumors

 

Research and publications.

Prognostic significance of high free T4 and low free T3 levels in non-thyroidal illness syndrome

…, D Kayaş, ET Canbaz, F Çetin, Ş Seçmeler… - European journal of …, 2018 - Elsevier

 

Background Non-thyroidal illness syndrome is characterized by decreased serum free T3 (FT3)

level and associates with long term mortality. Serum free T4 (FT4) may affect mortality …

 

Clinical and pathological characteristics of patients with high-risk breast cancer based on BRCA mutation profiles: a retrospective study

…, S Ay, A Sakin, B Ertürk, Ş Selections… - European journal of …, 2021 - ncbi.nlm.nih.gov

 

Objective: This study aimed to determine the differences in clinicopathological features of

Turkish patients with high-risk breast cancer based on the mutation status of two breast cancer …

Prognostic significance of mean platelet volume on local advanced non-small cell lung cancer managed with chemoradiotherapy

A Sakin, S Secmeler, S Arici, C Geredeli, N Yasar… - Scientific reports, 2019 - nature.com

 

Mean platelet volume (MPV), the most commonly used measure of platelet size, and is altered

in patients with malignancies. The aim of this study was to investigate the effect of MPV on …

 

The predictive role of metabolic tumor volume on no response to neoadjuvant chemotherapy in patients with breast cancer

…, C Geredeli, R Cekin, Ş Selections… - Journal of Oncology …, 2020 - journals.sagepub.com

 

Introduction To evaluate the predictive significance of pretreatment metabolic tumor volume

on pathologic response in patients who received neoadjuvant chemotherapy for breast …

 

Efficacy of trastuzumab and potential risk factors on survival in patients with HER2-positive metastatic gastric cancer

A Topcu, MM Atci, S Secmeler, M Besiroglu… - Future …, 2021 - Future Medicine

 

Aim: To evaluate the efficacy of trastuzumab and potential risk factors on survival in patients

with HER2-positive metastatic gastric cancer. Methods: We retrospectively included 138 …

The effects of diabetes and fasting plasma glucose on treatment of breast cancer with neoadjuvant chemotherapy

S Arici, C Geredeli, S Secmeler, R Cekin… - Current Problems in …, 2020 - Elsevier

Purpose To determine the effects of diabetes and fasting plasma glucose (FPG) level on the

pathologic response in patients with breast cancer who received neoadjuvant chemotherapy…

Major and minor salivary gland cancers: A multicenter retrospective study

…, NS Demirci, E Turkmen, T Şakalar, S Secmeler… - Head & …, 2023 - Wiley Online Library

Background Most of the studies on salivary gland cancers are limited for various reasons

such as being single‐center, small number of patients, including only major or minor SGCs, or …

Prognostic significance of primary tumor localization in stage II and III colon cancer

A Sakin, S Arici, S Secmeler, O Can… - World Journal of …, 2018 - ncbi.nlm.nih.gov

AIM To investigate the effects of tumor localization on disease free survival (DFS) and overall

survival (OS) in patients with stage II-III colon cancer. METHODS This retrospective study …

Factors affecting survival in neuroendocrine tumors: a 15-year single center experience

A Sakin, M Tambas, S Secmeler, O Can… - Asian Pacific Journal …, 2018 - ncbi.nlm.nih.gov

Background: Neuroendocrine tumors are a heterogeneous group of tumors that can originate

from all of the neuroendocrine cells in the body, mostly from the gastrointestinal tract. In…

The effect of body mass index on location of recurrence and survival in early-stage colorectal cancer

A Sakin, NS Samanci, S Secmeler, S Arici… - Journal of cancer …, 2020 - journals.lww.com

Materials and Methods: Patients that were followed up and treated in the Department of

Medical Oncology between 1999 and 2016 were retrospectively included in the study. patients…

 

Pretreatment Modified Glasgow Prognostic Score for Predicting Prognosis and Survival in Elderly Patients with Gastric Cancer Treated with Perioperative FLOT

E Melekoglu, E Bayram, S Secmeler, B Mete, B Sahin - Nutrients, 2023 - mdpi.com

Comparing the efficacy of regorafenib and 5-fluorouracil-based rechallenge chemotherapy in the third-line treatment of metastatic colorectal cancer

Potrebbe interessarti anche

Pagamenti e Benefici

I nostri servizi sono gratuiti

Il pagamento viene effettuato direttamente presso la clinica oppure tramite bonifico sul loro conto bancario ufficiale.

Prenotazione sicura

Alcune cliniche possono richiedere un deposito come parte della loro politica.

Pagamenti a rate flessibili

Paghi comodamente a rate flessibili.

Programma di raccomandazione

Ricevi premi per raccomandare Bookimed ai tuoi amici.